Q2 Earnings Forecast for Adicet Bio Issued By HC Wainwright

Key Points

• HC Wainwright has issued a “Buy” rating for Adicet Bio, with a price target of $4.00, estimating Q2 2025 earnings at ($0.32) EPS.
• The company reported earnings of ($0.31) EPS for the last quarter, which exceeded consensus estimates.
• Adicet Bio's stock has a market cap of $63.81 million and is primarily owned by institutional investors, who hold about 83.89% of the shares.

Adicet Bio, Inc. (NASDAQ:ACET - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Adicet Bio in a research report issued to clients and investors on Wednesday, July 23rd. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.32) for the quarter. HC Wainwright has a "Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Adicet Bio's current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio's Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.25) EPS, Q3 2026 earnings at ($0.30) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.18) EPS.

Adicet Bio (NASDAQ:ACET - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.03.

Separately, Wall Street Zen started coverage on Adicet Bio in a research note on Friday, May 16th. They issued a "hold" rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $6.00.

Adicet Bio Trading Down 0.8%

Shares of ACET traded down $0.01 during midday trading on Friday, reaching $0.77. 102,127 shares of the company were exchanged, compared to its average volume of 629,691. Adicet Bio has a 1-year low of $0.45 and a 1-year high of $1.70. The stock has a 50-day moving average price of $0.71 and a 200-day moving average price of $0.76. The company has a market cap of $63.27 million, a price-to-earnings ratio of -0.59 and a beta of 1.62.

Institutional Trading of Adicet Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of Adicet Bio during the fourth quarter worth $29,000. Wealthedge Investment Advisors LLC bought a new position in Adicet Bio in the 4th quarter valued at approximately $71,000. Vontobel Holding Ltd. raised its stake in shares of Adicet Bio by 33.3% during the second quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company's stock valued at $49,000 after acquiring an additional 20,000 shares during the last quarter. Northern Trust Corp raised its stake in shares of Adicet Bio by 25.1% during the fourth quarter. Northern Trust Corp now owns 140,369 shares of the company's stock valued at $135,000 after acquiring an additional 28,153 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Adicet Bio by 87.3% during the fourth quarter. JPMorgan Chase & Co. now owns 150,485 shares of the company's stock worth $145,000 after buying an additional 70,132 shares during the last quarter. Institutional investors and hedge funds own 83.89% of the company's stock.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.